Enzon Pharmaceuticals, Inc.
ENZN
$0.0808
-$0.0048-5.61%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -68.66% | 208.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -68.66% | 208.31% | |||
| Operating Income | 68.66% | -208.31% | |||
| Income Before Tax | -104.36% | -328.51% | |||
| Income Tax Expenses | -321.05% | -93.52% | |||
| Earnings from Continuing Operations | -88.93% | -627.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -88.93% | -627.78% | |||
| EBIT | 68.66% | -208.31% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -44.37% | -530.30% | |||
| Normalized Basic EPS | 137.21% | -326.32% | |||
| EPS Diluted | -44.37% | -530.30% | |||
| Normalized Diluted EPS | 137.21% | -326.32% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 1.00% | -- | |||